Literature DB >> 11469993

Augmented Visceral Perception.

William L. Hasler1.   

Abstract

Disorders of augmented visceral perception include functional (or nonulcer) dyspepsia and irritable bowel syndrome (IBS). Enhancement of luminal perception can result from alterations in normal elastic gut wall properties or exaggerated responsiveness of visceral sensory nerve pathways. Standard therapies for functional dyspepsia are effective in subsets of patients and may act in part by compensating for gastric hypersensitivity (as with acid-suppressing drugs) or by enhancing gastric compliance (as with some motor-stimulating agents). Likewise, conventional treatments of patients with IBS reduce visceral perception via effects on sensory nerve function (fiber supplements) or luminal wall properties (antispasmodic drugs). Antidepressants are increasingly used in patients with functional dyspepsia or IBS. These drugs have several purported mechanisms, including 1) luminal relaxation, 2) blunting of visceral hypersensitivity, and 3) modulation of central nervous system pain processing pathways. The efficacy of available and investigational agents that act as visceral analgesics or luminal relaxants is an area of intense pharmaceutical research.

Entities:  

Year:  2001        PMID: 11469993     DOI: 10.1007/s11938-001-0060-0

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  63 in total

1.  Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia.

Authors:  K McColl; L Murray; E El-Omar; A Dickson; A El-Nujumi; A Wirz; A Kelman; C Penny; R Knill-Jones; T Hilditch
Journal:  N Engl J Med       Date:  1998-12-24       Impact factor: 91.245

2.  Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function.

Authors:  M Thumshirn; M Camilleri; S B Saslow; D E Williams; D D Burton; R B Hanson
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

3.  Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia.

Authors:  J S Finney; N Kinnersley; M Hughes; C G O'Bryan-Tear; J Lothian
Journal:  J Clin Gastroenterol       Date:  1998-06       Impact factor: 3.062

Review 4.  AGA technical review: evaluation of dyspepsia. American Gastroenterological Association.

Authors:  N J Talley; M D Silverstein; L Agréus; O Nyrén; A Sonnenberg; G Holtmann
Journal:  Gastroenterology       Date:  1998-03       Impact factor: 22.682

5.  Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans.

Authors:  A B Gorelick; S S Koshy; F G Hooper; T C Bennett; W D Chey; W L Hasler
Journal:  Am J Physiol       Date:  1998-09

6.  Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects.

Authors:  A Prior; D G Maxton; P J Whorwell
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

7.  Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome.

Authors:  A Prior; N W Read
Journal:  Aliment Pharmacol Ther       Date:  1993-04       Impact factor: 8.171

8.  Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.

Authors:  M Dapoigny; J L Abitbol; B Fraitag
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

9.  The effect of octreotide on human gastric compliance and sensory perception.

Authors:  H Mertz; J H Walsh; B Sytnik; E A Mayer
Journal:  Neurogastroenterol Motil       Date:  1995-09       Impact factor: 3.598

10.  Oral domperidone in chronic postprandial dyspepsia. A double-blind placebo-controlled evaluation.

Authors:  L Van de Mierop; L Rutgeerts; B Van den Langenbergh; A Staessen
Journal:  Digestion       Date:  1979       Impact factor: 3.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.